JT
Therapeutic Areas
ARTBIO Pipeline
| Drug | Indication | Phase |
|---|---|---|
| AB001 (²¹²Pb-NG001) | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 1/2 |
| ABD | Triple-Negative Breast Cancer (TNBC), Head and Neck Squamous Cell Carcinoma (HNSCC) | Non-Clinical |
| ABA (²¹²Pb-undisclosed) | Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer | Non-Clinical |
| ABC (²¹²Pb-undisclosed) | Multiple Solid Tumors | Discovery |
| HEARTS | Multiple Solid Tumors (via Multiple Targets) | Discovery |
Leadership Team at ARTBIO
EO
Emanuele Ostuni, PhD
Founding CEO
JF
Jonathan Freeman, PhD
Chief Business Officer
MY
Margaret Yu, MD
Chief Medical Officer
PD
Philippe Dasse, PharmD
Chief Technical Officer
AD
Amra Demirovic
Chief Human Resources Officer
NH
Nicole Hadas
Chief Legal Officer
CW
Conrad Wüller, MSc
Vice President, Operations
CL
Calvin Lee, MBA
Vice President, Finance
JV
Jordi Vall-llosera Ferran, MSc
Head and Senior Vice President, Quality
VP
Victor Paulus, PhD
Head and Senior Vice President, Regulatory Affairs